Compounds > deferasirox
Page last updated: 2024-09-05

deferasirox and Neurodegenerative Diseases

deferasirox has been researched along with Neurodegenerative Diseases in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's7 (77.78)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Kondo, T; Miyake, Z; Nakamagoe, K; Tamaoka, A; Yoshida, K1
Aburakawa, Y; Kimura, T; Kono, S; Kuroda, K; Miyajima, H; Suzuki, Y; Terada, T; Yahara, O; Yoshida, K1
Amini, M; Atyabi, F; Dinarvand, R; Kamalinia, G; Khodagholi, F; Shaerzadeh, F; Sharifzadeh, M1
Grodde, T; Habeck, JO; Kirchhof, K; Lindner, U; Schleithoff, L; Schuppan, D; Stoelzel, U1
Bhathal, P; Doyle, A; Rusli, F1
Chattipakorn, N; Chattipakorn, SC; Krintratun, W; Sripetchwandee, J; Wongjaikam, S1
Bell, S; Calder, GL; Lee, MH; MacIsaac, RJ; Sachithanandan, N; Zeimer, H1
Bakry, R; Bonn, G; Bösch, S; Creus, M; Finkenstedt, A; Gasser, BI; Höfner, E; Janecke, AR; Kremser, C; Moser, P; Poewe, W; Schocke, M; Schranz, M; Theurl, M; Vogel, W; Wolf, E; Zoller, H1
Drago, V; Foster, P; Heilman, KM; Schmalfuss, IM; Skidmore, FM; Streiff, RR1

Reviews

2 review(s) available for deferasirox and Neurodegenerative Diseases

ArticleYear
Deferasirox Might Be Effective for Microcytic Anemia and Neurological Symptoms Associated with Aceruloplasminemia: A Case Report and Review of the Literature.
    Internal medicine (Tokyo, Japan), 2020, Jul-15, Volume: 59, Issue:14

    Topics: Adult; Anemia, Iron-Deficiency; Ceruloplasmin; Copper; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Male; Middle Aged; Neurodegenerative Diseases; Treatment Outcome; Young Adult

2020
Aceruloplasminaemia: a rare but important cause of iron overload.
    BMJ case reports, 2015, May-14, Volume: 2015

    Topics: Adult; Benzoates; Ceruloplasmin; Chelation Therapy; Deferasirox; Disease Progression; Early Diagnosis; Ferritins; Humans; Iron Chelating Agents; Iron Metabolism Disorders; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Neurodegenerative Diseases; Treatment Outcome; Triazoles

2015

Other Studies

7 other study(ies) available for deferasirox and Neurodegenerative Diseases

ArticleYear
Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:13

    Topics: Administration, Oral; Benzoates; Ceruloplasmin; Deferasirox; Humans; Iron Chelating Agents; Iron Metabolism Disorders; Male; Middle Aged; Mutation; Neurodegenerative Diseases; Treatment Outcome; Triazoles

2013
Enhanced brain delivery of deferasirox-lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: in vitro and in vivo studies.
    Molecular pharmaceutics, 2013, Dec-02, Volume: 10, Issue:12

    Topics: Alzheimer Disease; Animals; Apoptosis; Apoptosis Regulatory Proteins; Benzoates; Brain; Carbodiimides; Cell Line, Tumor; Chelating Agents; Chelation Therapy; Deferasirox; Disease Models, Animal; Drug Delivery Systems; Iron; Lactoferrin; Male; Nanostructures; Neurodegenerative Diseases; Neuroprotective Agents; PC12 Cells; Permeability; Rats; Rats, Wistar; Transcytosis; Triazoles

2013
Aceruloplasminaemia: a family with a novel mutation and long-term therapy with deferasirox.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2015, Volume: 47, Issue:4

    Topics: Adult; Benzoates; Blood Glucose; Ceruloplasmin; Chelating Agents; Chromosomes, Human, Pair 3; Deferasirox; Female; Germany; Humans; Iron; Iron Metabolism Disorders; Liver; Magnetic Resonance Imaging; Male; Mutation; Neurodegenerative Diseases; Pedigree; Treatment Outcome; Triazoles

2015
A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload.
    Neuroscience, 2016, 09-22, Volume: 332

    Topics: Acetylcysteine; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Benzoates; Brain; Deferasirox; Deferoxamine; Dendrites; Diet; Disease Models, Animal; Drug Therapy, Combination; Iron; Iron Chelating Agents; Iron Overload; Male; Mitochondrial Dynamics; Neurodegenerative Diseases; Phosphorylation; Random Allocation; Rats, Wistar; tau Proteins; Triazoles

2016
Aceruloplasminaemia: a disorder of diabetes and neurodegeneration.
    Internal medicine journal, 2017, Volume: 47, Issue:1

    Topics: Adult; Benzoates; Brain; Ceruloplasmin; Copper; Deferasirox; Diabetes Mellitus, Type 2; Diagnosis, Differential; Ferritins; Humans; Insulin; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Magnetic Resonance Imaging; Male; Neurodegenerative Diseases; Triazoles

2017
Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.
    Journal of hepatology, 2010, Volume: 53, Issue:6

    Topics: Antimicrobial Cationic Peptides; Benzoates; Brain; Ceruloplasmin; Consanguinity; Deferasirox; Female; Hepcidins; Homozygote; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Liver; Male; Middle Aged; Mutation; Neurodegenerative Diseases; Pedigree; RNA, Messenger; Triazoles

2010
Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation.
    Journal of neurology, neurosurgery, and psychiatry, 2008, Volume: 79, Issue:4

    Topics: Atrophy; Benzoates; Biopsy; Brain; Ceruloplasmin; Chelation Therapy; Chorea; Deferasirox; Diagnosis, Differential; Disease Progression; Female; Ferritins; Gait Disorders, Neurologic; Humans; Iron Overload; Liver; Magnetic Resonance Imaging; Middle Aged; Muscle Spasticity; Muscle, Skeletal; Neurodegenerative Diseases; Neurologic Examination; Neuropsychological Tests; Spleen; Triazoles

2008